0.10
+1.93%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Prostatype Genomics
Its shares trade on Nasdaq Stockholm under the ticker PROGEN.ST. It has been listed since 3 November 2020. In the fiscal year to 31 December 2025, it reported revenue of SEK 594,000 and a net loss of SEK 44.5m. At that date it held total assets of SEK 50.9m and shareholders' equity of SEK 26.5m.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. The company is headquartered in Solna, Stockholm. The company went IPO on 2020-11-03. The firm's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Nov 2020
- Website
- prostatypegenomics.com ↗
Leadership
Pay as last reported
- Fredrik PerssonChief Executive Officer, since 2017
- Michael af Winklerfelt, MBAChief Operating & Financial Officer, since 2020
- Lidi Xu, PhDChief Technology Officer, since 2019
- Dilruba Ahmed, PhDManager-Quality Control, since 2019
- Joakim HagvikManager-Sales & Marketing, since 2017
- Anders LundbergChairman, since 2017
- Christoph Petry, PhDDirector, since 2019
- Karlheinz Schmelig, MBADirector, since 2013
- Bengt Håkan EnglundDirector, since 2019
- Michael Häggman, MD, PhDDirector, since 2018
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Prostatype Genomics AB manufactures the Prostatype RTqPCR kit for prostate cancer gene testing.
- The company's Prostatype Test System includes patient database and evaluation software for treatment decisions.
- Prostatype Genomics AB's business model focuses on selling a complete prognostic package for prostate cancer.
Weaknesses
- Prostatype Genomics AB's IPO occurred on 3 November 2020, limiting recent market expansion.
- The company's business model relies solely on the Prostatype Test System without diversification.
- Prostatype Genomics AB has no other products or services beyond the Prostatype Test System.
Opportunities
- Prostatype Genomics AB can expand its market in the Health Care sector for prostate cancer testing.
- The company can leverage the Prostatype Test System in the Swedish market for prostate cancer treatment decisions.
- Prostatype Genomics AB can target the European market for its gene expression analysis services.
Threats
- Prostatype Genomics AB faces competition from other biotechnology firms in the Health Care sector.
- The company's reliance on a single product, the Prostatype Test System, poses a risk.
- Prostatype Genomics AB must navigate regulatory challenges in the Health Care industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.